Related Experiment Video

Updated: Jun 27, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases

Yan Shi1, Conggao Xu

  • 1Department of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, PR China.

Recent Patents on DNA & Gene Sequences
|December 17, 2008
PubMed

Insights

Recent patents focus on JAK2 mutations, crucial for diagnosing and treating myeloproliferative diseases like polycythemia vera. These innovations target specific polynucleotide sequences and novel JAK2 inhibitors for personalized therapies.

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • The JAK/STAT pathway regulates hematopoietic cell proliferation and differentiation.
  • JAK family kinases (JAK1, JAK2, JAK3, tyrosine kinase 2) are critical in cellular signaling.
  • JAK2 mutations, including JAK2V617F and exon 12 mutations, are prevalent in myeloproliferative neoplasms.

Purpose of the Study:

  • To review recent patents concerning JAK2 mutations.
  • To highlight advancements in diagnostic methods for JAK2-specific polynucleotide sequences.
  • To discuss novel pharmacological JAK2 inhibitors for targeted therapy.

Main Methods:

  • Review of patent literature related to JAK2 mutations.
  • Analysis of patents covering diagnostic methods for JAK2 genetic alterations.
  • Examination of patents for small molecule JAK2 inhibitors.

Main Results:

  • Identification of key patents in JAK2 mutation detection.
  • Overview of patented strategies for developing JAK2-targeted therapies.
  • Summary of recent advancements in drug development for JAK2-mutated diseases.

Conclusions:

  • JAK2 mutation discovery has significantly improved diagnosis of chronic myeloproliferative diseases.
  • Patented technologies offer new avenues for identifying and treating JAK2-driven malignancies.
  • Ongoing patent activity underscores the therapeutic potential of targeting JAK2 in hematological disorders.

More Related Videos

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...